INHIBRX BIOSCIENCES, INC. Operating Lease, Expense
INHIBRX BIOSCIENCES, INC. (INBX) reported Operating Lease, Expense of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. operating lease, expense for the quarter ending 2026-06-30 was $1.00M, a 11.11% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for the quarter ending 2026-03-31 was $1.10M, a 22.22% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for the quarter ending 2025-12-31 was $1.00M, a 11.11% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for the quarter ending 2025-09-30 was $1.00M, a 11.11% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for fiscal 2025 was $3.90M, a 14.71% increase from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for fiscal 2024 was $3.40M, a 8.11% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. operating lease, expense for fiscal 2023 was $3.70M.
| Period end | Operating Lease, Expense | Operating Lease, Expense 1 month | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-13 | $2.10M 10-Q · filed 2026-08-13 | $3.10M derived: sum of 3 quarters · filed 2026-08-13 | $4.10M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-14 | $2.10M derived: sum of 2 quarters · filed 2026-05-14 | $3.10M derived: sum of 3 quarters · filed 2026-05-14 | $4.00M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.00M derived: sum of 2 quarters · filed 2026-03-19 | $2.90M derived: sum of 3 quarters · filed 2026-08-13 | $3.90M 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-14 | $1.90M derived: sum of 2 quarters · filed 2026-08-13 | $2.90M 10-Q · filed 2025-11-14 | $3.70M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $900.00K 10-Q · filed 2026-08-13 | $1.90M 10-Q · filed 2026-08-13 | $2.70M derived: sum of 3 quarters · filed 2026-08-13 | $3.60M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $900.00K 10-Q · filed 2026-05-14 | $1.80M derived: sum of 2 quarters · filed 2026-05-14 | $2.70M derived: sum of 3 quarters · filed 2026-05-14 | $3.50M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.80M derived: sum of 2 quarters · filed 2026-03-19 | $2.60M derived: sum of 3 quarters · filed 2026-03-19 | $3.40M 10-K · filed 2026-03-19 | ||
| 2024-11-30 | $200.00K 10-K · filed 2026-03-19 | |||||
| 2024-11-12 | $200.00K 10-Q · filed 2025-05-14 | |||||
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-14 | $1.70M derived: sum of 2 quarters · filed 2025-11-14 | $2.50M 10-Q · filed 2025-11-14 | $3.60M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-13 | $1.60M 10-Q · filed 2025-08-13 | $2.70M derived: sum of 3 quarters · filed 2025-08-13 | $3.60M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-14 | $1.90M derived: sum of 2 quarters · filed 2025-05-14 | $2.80M derived: sum of 3 quarters · filed 2025-05-14 | $3.60M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.00M derived: sum of 2 quarters · filed 2025-03-17 | $2.80M derived: sum of 3 quarters · filed 2025-03-17 | $3.70M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-14 | $1.70M derived: sum of 2 quarters · filed 2024-11-14 | $2.60M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-13 | $1.70M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |